Latest Cyclacel Pharmaceuticals (CYCC) Headlines
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room.
Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014.
Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH
GlobeNewswire - Mon Dec 09, 6:00AM CST
- Nearly Doubles Expected Median Survival of Older Patients with MDS after Treatment Failure of Hypomethylating Agents -
Cyclacel Pharmaceuticals Up 5.5%, Shares Break Through Resistance (CYCC)
Comtex SmarTrend(R) - Mon Nov 25, 10:28AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 5.5% to $4.58 on 1.3x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 391,000 shares, vs. average volume of 313,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.2%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Mon Nov 25, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its third planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 212 randomized patients and noted that no safety or efficacy concerns were identified. The DSMB will conduct additional periodic reviews of each 100 patients and will also perform a futility assessment once half the required events have been observed.
Hot Stock: Cyclacel Pharmaceuticals, Shares Gain 6.4% (CYCC)
Comtex SmarTrend(R) - Thu Nov 14, 10:15AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 6.4% to $4.16 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 443,000 shares, vs. average volume of 318,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.3%) during today's trading.
Cyclacel Reports Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today reported its financial results and business highlights for the third quarter ended September 30, 2013. The net loss for the third quarter of 2013 was $5.0 million versus a net loss for the third quarter of 2012 of $1.9 million. As of September 30, 2013, cash and cash equivalents totaled $34.5 million. The Company's net loss applicable to common shareholders for the third quarter of 2013 was $5.7 million, which includes $2.6 million of expense related to clinical trial drug supply, or $0.32 per basic and diluted share, compared to a net loss applicable to common shareholders of $2.1 million or $0.25 per basic and diluted share for the third quarter of 2012.
Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting
GlobeNewswire - Thu Nov 07, 8:39AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that researchers will present new data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine, at the 55th Annual Meeting of the American Society of Hematology (ASH). The data include the primary endpoint of one year survival which will enable selection of a dosing schedule for a Phase 3 study.
Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results
GlobeNewswire - Wed Nov 06, 6:30AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce third quarter 2013 financial results on Tuesday, November 12, 2013. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens
GlobeNewswire - Tue Nov 05, 6:30AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the US Patent and Trademark Office (USPTO) issued two patents extending the exclusivity of sapacitabine, the Company's lead clinical candidate. The first patent claims, among others, methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors, including azacitidine and decitabine. The second patent claims methods of use for sapacitabine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including the dosing regimen used in SEAMLESS, the Company's ongoing, pivotal, registration-directed, Phase 3 study in front-line elderly AML.
Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference
GlobeNewswire - Thu Oct 31, 3:10PM CDT
- Sapacitabine Named as a "Top Project to Watch" in Oncology by Elsevier Business Intelligence -
Nasdaq stocks posting largest volume increases
AP - Fri Sep 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
SmallCapReview.com - Small Cap Stocks To Watch - CYCC, VRNM
M2 - Fri Sep 20, 7:04AM CDT
Cyclacel Pharmaceuticals (Nasdaq: CYCC) $3.80. Announced Thursday after market close updated data showing that sapacitabine has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors.
Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer
GlobeNewswire - Thu Sep 19, 3:30PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced updated data showing that sapacitabine has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors. The data were reported at a poster presentation during the American Association of Cancer Research (AACR) conference "Advances in Ovarian Cancer: from concept to clinic" being held September 18-21, 2013, in Miami, FL.
Traders Get Bullish on Shares of Cyclacel Pharmaceuticals, Shares Up 10.4% (CYCC)
Comtex SmarTrend(R) - Thu Sep 19, 11:44AM CDT
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 10.4% to $3.71 on 1.3x average daily volume. Cyclacel Pharmaceuticals has traded 314,000 shares thus far today, vs. average volume of 241,000 shares per day. The stock has outperformed the Dow (10.4% to the Dow's -0.2%) and outperformed the S&P 500 (10.4% to the S&P's -0.1%) during today's trading.
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 16th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 10, 2014 at 11:00 a.m. Eastern in the Duke of Windsor room.
Investors look to Lighten Up on Shares of Cyclacel Pharmaceuticals, Shares Down 6.2% (CYCC)
Comtex SmarTrend(R) - Mon Jan 27, 12:46PM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 6.2% to $3.60 on 1.4x average daily volume. Cyclacel Pharmaceuticals has traded 384,000 shares thus far today, vs. average volume of 284,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's -0.2%) and underperformed the S&P 500 (-6.2% to the S&P's -0.5%) during today's trading.
Ubiquiti inks distribution agreement with Ingram Micro
M2 - Thu Jan 16, 8:22AM CST
Ubiquiti Networks, Inc. (NASDAQ: UBNT) said it has announced a US distribution agreement with Ingram Micro Inc. (NYSE: IM).
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014
GlobeNewswire - Mon Jan 13, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) today reviewed 2013 achievements and provided an outline of the Company's key clinical development objectives for 2014, which will be highlighted at the Company's presentation during the Biotech Showcase(TM) 2014 Conference at 9:30 a.m. PST, Monday, Jan. 13, 2014, at the Parc 55 Wyndham Hotel - Union Square at 55 Cyril Magnin Street in San Francisco.
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference
GlobeNewswire - Mon Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2014 conference being held at Parc 55 Wyndham San Francisco - Union Square at 55 Cyril Magnin Street, San Francisco, Calif. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 9:30 a.m. PST on Monday, January 13, 2014.
Cyclacel Pharmaceuticals Down 10.2%, Shares Slide into the Red (CYCC)
Comtex SmarTrend(R) - Mon Dec 09, 11:43AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's worst performing low-priced stocks, down 10.2% to $4.32 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 487,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-10.2% to the Dow's 0.1%) and underperformed the S&P 500 (-10.2% to the S&P's 0.3%) during today's trading.
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH
GlobeNewswire - Mon Dec 09, 6:00AM CST
- Nearly Doubles Expected Median Survival of Older Patients with MDS after Treatment Failure of Hypomethylating Agents -
Cyclacel Pharmaceuticals Up 5.5%, Shares Break Through Resistance (CYCC)
Comtex SmarTrend(R) - Mon Nov 25, 10:28AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 5.5% to $4.58 on 1.3x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 391,000 shares, vs. average volume of 313,000 shares per day. The stock has outperformed the Dow (5.5% to the Dow's 0.2%) and outperformed the S&P 500 (5.5% to the S&P's 0.0%) during today's trading.
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
GlobeNewswire - Mon Nov 25, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the independent Data and Safety Monitoring Board (DSMB) for the Company's Phase 3 SEAMLESS study in acute myeloid leukemia (AML) has completed its third planned safety review and recommended that the study should continue as planned without any modifications. The DSMB reviewed available data from 212 randomized patients and noted that no safety or efficacy concerns were identified. The DSMB will conduct additional periodic reviews of each 100 patients and will also perform a futility assessment once half the required events have been observed.
Hot Stock: Cyclacel Pharmaceuticals, Shares Gain 6.4% (CYCC)
Comtex SmarTrend(R) - Thu Nov 14, 10:15AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 6.4% to $4.16 on 1.4x average daily volume. Thus far today, Cyclacel Pharmaceuticals has traded 443,000 shares, vs. average volume of 318,000 shares per day. The stock has outperformed the Dow (6.4% to the Dow's 0.3%) and outperformed the S&P 500 (6.4% to the S&P's 0.3%) during today's trading.
Cyclacel Reports Third Quarter 2013 Financial Results
GlobeNewswire - Tue Nov 12, 3:05PM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today reported its financial results and business highlights for the third quarter ended September 30, 2013. The net loss for the third quarter of 2013 was $5.0 million versus a net loss for the third quarter of 2012 of $1.9 million. As of September 30, 2013, cash and cash equivalents totaled $34.5 million. The Company's net loss applicable to common shareholders for the third quarter of 2013 was $5.7 million, which includes $2.6 million of expense related to clinical trial drug supply, or $0.32 per basic and diluted share, compared to a net loss applicable to common shareholders of $2.1 million or $0.25 per basic and diluted share for the third quarter of 2012.
Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH Annual Meeting
GlobeNewswire - Thu Nov 07, 8:39AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that researchers will present new data from an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine, at the 55th Annual Meeting of the American Society of Hematology (ASH). The data include the primary endpoint of one year survival which will enable selection of a dosing schedule for a Phase 3 study.
Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results
GlobeNewswire - Wed Nov 06, 6:30AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders will announce third quarter 2013 financial results on Tuesday, November 12, 2013. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing Regimens
GlobeNewswire - Tue Nov 05, 6:30AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that the US Patent and Trademark Office (USPTO) issued two patents extending the exclusivity of sapacitabine, the Company's lead clinical candidate. The first patent claims, among others, methods of treating cancer comprising sapacitabine together with DNA methyltransferase inhibitors, including azacitidine and decitabine. The second patent claims methods of use for sapacitabine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), including the dosing regimen used in SEAMLESS, the Company's ongoing, pivotal, registration-directed, Phase 3 study in front-line elderly AML.
Cyclacel Pharmaceuticals to Present at the 2013 Therapeutic Area Partnerships Conference
GlobeNewswire - Thu Oct 31, 3:10PM CDT
- Sapacitabine Named as a "Top Project to Watch" in Oncology by Elsevier Business Intelligence -
Nasdaq stocks posting largest volume increases
AP - Fri Sep 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
SmallCapReview.com - Small Cap Stocks To Watch - CYCC, VRNM
M2 - Fri Sep 20, 7:04AM CDT
Cyclacel Pharmaceuticals (Nasdaq: CYCC) $3.80. Announced Thursday after market close updated data showing that sapacitabine has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors.
Cyclacel's Sapacitabine Reported to Have Anti-Tumor Activity Against Ovarian Cancer
GlobeNewswire - Thu Sep 19, 3:30PM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced updated data showing that sapacitabine has activity against a majority of ovarian cancer samples taken from patients, including resistant tumors. The data were reported at a poster presentation during the American Association of Cancer Research (AACR) conference "Advances in Ovarian Cancer: from concept to clinic" being held September 18-21, 2013, in Miami, FL.
Traders Get Bullish on Shares of Cyclacel Pharmaceuticals, Shares Up 10.4% (CYCC)
Comtex SmarTrend(R) - Thu Sep 19, 11:44AM CDT
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 10.4% to $3.71 on 1.3x average daily volume. Cyclacel Pharmaceuticals has traded 314,000 shares thus far today, vs. average volume of 241,000 shares per day. The stock has outperformed the Dow (10.4% to the Dow's -0.2%) and outperformed the S&P 500 (10.4% to the S&P's -0.1%) during today's trading.
